Want to see JP:4571 full AI Analyst Report?
NanoCarrier Co., Ltd. (4571) AI Stock Analysis
NanoCarrier Co., Ltd.
(TSE/TYO:4571)
The overall score is at the minimum of 37, reflecting a high-risk profile. The most significant factors are the company's deep unprofitability and negative cash flows, which are critical weaknesses for a pre-revenue stage biotechnology firm. This is compounded by a persistently bearish technical trend, with the stock trading far below key moving averages. The only mitigating factor is a solid balance sheet, which provides a temporary financial runway but does not offset the fundamental and market-driven risks.
NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.18B
- Dividend Yield
- ―
- Average Volume (3M)
- 651.67K
- Price to Earnings (P/E)
- -5.9
- Beta (1Y)
- 0.92
- Revenue Growth
- 74.24%
- EPS Growth
- -7.78%
- Country
- Japan
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
NanoCarrier Co., Ltd. Business Overview & Revenue Model
Company Description
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 P...
NanoCarrier Co., Ltd. Financial Statement Overview
Summary
Financial performance is weak. The income statement shows deep net losses despite high gross margins and revenue growth, and cash flow is significantly negative, indicating a high cash burn rate. The balance sheet is the only bright spot, providing a solid equity base and moderate leverage.
Income Statement
20Very NegativeBalance Sheet
70PositiveCash Flow
25Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 202.50M | 174.50M | 108.52M | 135.51M | 202.19M | 264.03M |
| Gross Profit | 179.88M | 153.29M | 78.17M | 110.96M | 159.60M | 220.88M |
| EBITDA | -1.00B | -892.12M | -832.57M | -776.41M | -1.30B | -1.87B |
| Net Income | -1.02B | -943.88M | -835.38M | -780.00M | -1.31B | -1.88B |
Balance Sheet | ||||||
| Total Assets | 5.24B | 5.91B | 4.00B | 5.07B | 5.78B | 7.14B |
| Cash, Cash Equivalents and Short-Term Investments | 4.22B | 4.91B | 3.51B | 4.28B | 4.44B | 5.95B |
| Total Debt | 1.20B | 1.60B | 540.24M | 1.11B | 1.11B | 1.15B |
| Total Liabilities | 1.92B | 2.34B | 1.26B | 1.65B | 1.53B | 1.57B |
| Stockholders Equity | 3.31B | 3.57B | 2.74B | 3.42B | 4.25B | 5.57B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | 0 | -585.08M | -1.09B | -1.76B |
| Operating Cash Flow | 0 | -816.67M | -401.62M | -585.08M | -1.09B | -1.75B |
| Investing Cash Flow | 0 | 2.26B | 587.53M | 793.01M | 1.21B | -244.13M |
| Financing Cash Flow | 0 | 2.22B | -568.77M | 3.73M | 32.20M | 1.15B |
NanoCarrier Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 79.00 is below the 20-day moving average (MA) of 82.45, below the 50-day MA of 93.82, and below the 200-day MA of 122.87, indicating a bearish trend. The MACD of -4.28 indicates Negative momentum. The RSI at 42.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.
NanoCarrier Co., Ltd. Peers Comparison
Overall Rating
JP:458850Neutral
JP:456446Neutral
JP:458340Underperform- JP:457137Underperform
JP:488833Underperform
JP:456331Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4588 | 50Neutral | JPY 223.32B | -137.55 | ― | ― | 1662.38% | 42.86% |
| JP:4564 | 46Neutral | JPY 7.35B | -7.63 | -42.79% | ― | -8.58% | 19.03% |
| JP:4583 | 40Underperform | JPY 7.29B | -6.79 | ― | ― | -19.99% | 16.36% |
| JP:4571 | 37Underperform | JPY 7.18B | -5.87 | -33.61% | ― | 74.24% | -7.78% |
| JP:4888 | 33Underperform | JPY 15.22B | -16.51 | ― | ― | -67.40% | -524.23% |
| JP:4563 | 31Underperform | JPY 11.75B | -3.04 | -163.39% | ― | 35.28% | 90.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4571 | NanoCarrier Co., Ltd. | 79.00 | -81.00 | -50.63% | |
| JP:4563 | AnGes | 29.00 | -58.00 | -66.67% | |
| JP:4564 | OncoTherapy Science, Inc. | 18.00 | -6.00 | -25.00% | |
| JP:4583 | Chiome Bioscience Inc. | 89.00 | -39.00 | -30.47% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7560.00 | 6795.00 | 888.24% | |
| JP:4888 | STELLA PHARMA CORPORATION | 411.00 | 100.00 | 32.15% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026